Stock data
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS) reported revenue of US$2.19M and net income of -US$24.19M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$2.19M | — | -US$87.98M | -US$24.19M | — |
| 2024 | US$3.61M | — | -US$89.15M | -US$131.21M | — |
| 2023 | US$6.19M | — | -US$88.13M | -US$87.68M | — |
| 2022 | US$0.00M | — | -US$97.58M | -US$96.05M | — |
| 2021 | US$0.00M | — | -US$128.32M | -US$128.33M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$1.50M | — |
| 2026-03-31 | US$2.83M | -US$23.04M | — |
| 2025-12-31 | US$0.17M | -US$19.88M | — |
| 2025-09-30 | US$0.74M | -US$31.54M | — |
| 2025-06-30 | US$0.96M | -US$15.86M | — |
| 2025-03-31 | US$0.31M | US$43.09M | — |
| 2024-12-31 | US$0.61M | -US$82.15M | — |
| 2024-09-30 | US$1.25M | -US$19.26M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.